Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to slow down the progression of geographic atrophy.

A new provision decreeing basic eye services will not be allowed to be billed on the same day as medically necessary eye care for children or seniors is expected to hit those with difficulties ...

AI-powered research on one of the largest eye studies to date has created the most detailed maps of the retina ever produced.

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including ...

Our vision declines as we age leading to the development of various eye conditions such as presbyopia cataracts and glaucoma ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...